Clinical Trials
3 trialsNCT00739453 2024-11-20
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Astellas Pharma Inc
Phase 1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed